Vaso-Occlusive Crisis

In this episode of Meeting Mic, we bring you expert insights from the ASH Annual Meeting and Exhibition, as well as Healio’s top headlines from the meeting.

IV lactated Ringer solution should be the preferred volume-expanding fluid for resuscitation of patients with sickle cell disease who experience vaso-occlusive episodes at the time of hospital admission, according to study results.

SAN DIEGO — One-time treatment with lovotibeglogene autotemcel gene therapy conferred “transformative” benefit to patients with sickle cell disease, according to a presenter at ASH Annual Meeting and Exposition.

ASH recognized three Choosing Wisely champions and three guideline implementation champions at this year’s ASH Annual Meeting and Exposition.

Exposure to systemic corticosteroids appeared to increase risk for hospitalization for vaso-occlusive episodes among patients with sickle cell disease, according to a French study published in Blood.

According to one patient undergoing treatment for sickle cell disease at University Hospitals Connor Whole Health, pain associated with the disease “feels like someone’s constantly stabbing you, but you’re not dying.”

Sickle cell disease is the most common genetic disorder, affecting approximately 100,000 people in the United States.

The FDA granted orphan drug designation to CSL889 for the treatment of sickle cell disease, according to the agent’s manufacturer.

Vaporized cannabis did not significantly reduce chronic pain and most associated symptoms compared with placebo among adults with sickle cell disease, according to results of a randomized study published in JAMA Network Open.

Escalated dosing of hydroxyurea had greater clinical efficacy than fixed dosing of the drug for children with sickle cell disease in sub-Saharan Africa, according to randomized study results published in The New England Journal of Medicine.